BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carothers JJ, Bruce MG, Hennessy TW, Bensler M, Morris JM, Reasonover AL, Hurlburt DA, Parkinson AJ, Coleman JM, McMahon BJ. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis. 2007;44:e5-e8. [PMID: 17173210 DOI: 10.1086/510074] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Abd-Elsalam S, Kobtan A, El-Kalla F, Elkhalawany W, Nawasany SE, Saif SA, Yousef M, Ali LA, Soliman S, Mansour L, Habba E, Soliman H, Rizk F, Shehata MA. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore) 2016;95:e3879. [PMID: 27310977 DOI: 10.1097/MD.0000000000003879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
2 Wang LH, Cheng H, Hu FL, Li J. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 2010; 16(18): 2272-2277 [PMID: 20458765 DOI: 10.3748/wjg.v16.i18.2272] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
3 Yamamoto T, Takano T, Higuchi W, Nishiyama A, Taneike I, Yoshida K, Kanda H, Imamura Y. Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. Antimicrob Agents Chemother 2011;55:4261-6. [PMID: 21730117 DOI: 10.1128/AAC.01105-10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Selgrad M, Kandulski A, Malfertheiner P. Helicobacter pylori: diagnosis and treatment. Curr Opin Gastroenterol. 2009;25:549-556. [PMID: 19696666 DOI: 10.1097/mog.0b013e32833159f2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 Bruden DL, Bruce MG, Miernyk KM, Morris J, Hurlburt D, Hennessy TW, Peters H, Sacco F, Parkinson AJ, McMahon BJ. Diagnostic accuracy of tests for Helicobacter pylori in an Alaska Native population. World J Gastroenterol 2011; 17(42): 4682-4688 [PMID: 22180710 DOI: 10.3748/wjg.v17.i42.4682] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
6 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014; 5(4): 392-399 [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
7 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
8 Caro SD, Fini L, Daoud Y, Grizzi F, Gasbarrini A, Lorenzo AD, Renzo LD, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18(40): 5669-5678 [PMID: 23155306 DOI: 10.3748/wjg.v18.i40.5669] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
9 Lawson AJ. Helicobacter. In: Jorgensen JH, Carroll KC, Funke G, Pfaller MA, Landry ML, Richter SS, Warnock DW, editors. Manual of Clinical Microbiology. Washington: ASM Press; 2015. pp. 1013-27. [DOI: 10.1128/9781555817381.ch57] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
10 Krzyżek P, Pawełka D, Iwańczak B, Kempiński R, Leśniakowski K, Mégraud F, Łaczmański Ł, Biernat M, Gościniak G. High Primary Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric and Adult Patients in Poland during 2016-2018. Antibiotics (Basel) 2020;9:E228. [PMID: 32370201 DOI: 10.3390/antibiotics9050228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Kong S, Chen H, Huang K, Jin D, Zhang G, Ye F. Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report. Medicine (Baltimore) 2021;100:e24915. [PMID: 33725850 DOI: 10.1097/MD.0000000000024915] [Reference Citation Analysis]
12 Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, Barrio J, Bory F, Almela P, Sánchez-Pobre P. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol. 2008;103:71-76. [PMID: 17764498 DOI: 10.1111/j.1572-0241.2007.01500.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
13 Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther. 2010;8:59-70. [PMID: 20014902 DOI: 10.1586/eri.09.113] [Cited by in Crossref: 74] [Cited by in F6Publishing: 79] [Article Influence: 6.7] [Reference Citation Analysis]
14 Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. J Med Microbiol. 2012;61:85-93. [PMID: 21873378 DOI: 10.1099/jmm.0.035568-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
15 Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011;16:420-426. [PMID: 22059392 DOI: 10.1111/j.1523-5378.2011.00867.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
16 Mosites E, Bruden D, Morris J, Reasonover A, Rudolph K, Hurlburt D, Hennessy T, McMahon B, Bruce M. Antimicrobial resistance among Helicobacter pylori isolates in Alaska, 2000-2016. J Glob Antimicrob Resist 2018;15:148-53. [PMID: 29969753 DOI: 10.1016/j.jgar.2018.06.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
17 黄桂柳, 黄赞松. 左氧氟沙星抗幽门螺杆菌感染的耐药性与安全性. 世界华人消化杂志 2014; 22(28): 4301-4305 [DOI: 10.11569/wcjd.v22.i28.4301] [Reference Citation Analysis]
18 Olesen SW, Barnett ML, MacFadden DR, Brownstein JS, Hernández-Díaz S, Lipsitch M, Grad YH. The distribution of antibiotic use and its association with antibiotic resistance. Elife 2018;7:e39435. [PMID: 30560781 DOI: 10.7554/eLife.39435] [Cited by in Crossref: 57] [Cited by in F6Publishing: 28] [Article Influence: 19.0] [Reference Citation Analysis]
19 Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206-214. [PMID: 23241101 DOI: 10.1111/hel.12031] [Cited by in Crossref: 172] [Cited by in F6Publishing: 144] [Article Influence: 19.1] [Reference Citation Analysis]
20 Rhie SY, Park JY, Shin TS, Kim JW, Kim BJ, Kim JG. Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in Korea. Antibiotics (Basel) 2020;9:E287. [PMID: 32471292 DOI: 10.3390/antibiotics9060287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926.Epub2012Jun19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Tveit AH, Bruce MG, Bruden DL, Morris J, Reasonover A, Hurlburt DA, Hennessy TW, McMahon B. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol. 2011;49:3638-3643. [PMID: 21813726 DOI: 10.1128/jcm.01067-11] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
23 Keck JW, Miernyk KM, Bulkow LR, Kelly JJ, McMahon BJ, Sacco F, Hennessy TW, Bruce MG. Helicobacter pylori infection and markers of gastric cancer risk in Alaska Native persons: a retrospective case-control study. Can J Gastroenterol Hepatol 2014;28:305-10. [PMID: 24945184 DOI: 10.1155/2014/892084] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
24 Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract 2012;2012:757926. [PMID: 22778723 DOI: 10.1155/2012/757926] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
25 Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol. 2009;24:1230-1235. [PMID: 19476562 DOI: 10.1111/j.1440-1746.2009.05829.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
26 Wueppenhorst N, Stueger HP, Kist M, Glocker E. Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother. 2009;63:648-653. [PMID: 19190100 DOI: 10.1093/jac/dkp003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
27 Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14(35): 5385-5402 [PMID: 18803350 DOI: 10.3748/wjg.14.5385] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 77] [Article Influence: 6.1] [Reference Citation Analysis]
28 Miernyk K, Morris J, Bruden D, McMahon B, Hurlburt D, Sacco F, Parkinson A, Hennessy T, Bruce M. Characterization of Helicobacter pylori cagA and vacA genotypes among Alaskans and their correlation with clinical disease. J Clin Microbiol. 2011;49:3114-3121. [PMID: 21752979 DOI: 10.1128/jcm.00469-11] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
29 Kang KK, Lee DH, Oh DH, Yoon H, Shin CM, Park YS, Kim N, Jung HC. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014; 20(22): 6932-6938 [PMID: 24944485 DOI: 10.3748/wjg.v20.i22.6932] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
30 Gisbert JP. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol. 2009;2:331-356. [PMID: 21180581 DOI: 10.1177/1756283x09347109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
31 吴李培, 宣世海. 幽门螺杆菌对左氧氟沙星耐药的研究进展. 世界华人消化杂志 2014; 22(2): 197-202 [DOI: 10.11569/wcjd.v22.i2.197] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Vakil N, Megraud F. Eradication Therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001. [DOI: 10.1053/j.gastro.2007.07.008] [Cited by in Crossref: 154] [Cited by in F6Publishing: 151] [Article Influence: 11.0] [Reference Citation Analysis]
33 Rispo A, Capone P, Castiglione F, Pasquale L, Rea M, Caporaso N. Fluoroquinolone-based protocols for eradication of Helicobacter pyloriWorld J Gastroenterol 2014; 20(27): 8947-8956 [PMID: 25083067 DOI: 10.3748/wjg.v20.i27.8947] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
34 Hung IF, Chan P, Leung S, Chan FS, Hsu A, But D, Seto WK, Wong SY, Chan CK, Gu Q. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter. 2009;14:505-511. [PMID: 19889067 DOI: 10.1111/j.1523-5378.2009.00722.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
35 Chisholm SA, Owen RJ. Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK. J Med Microbiol. 2009;58:1322-1328. [PMID: 19589906 DOI: 10.1099/jmm.0.011270-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
36 Bayati S, Alebouyeh M, Amirmozafari N, Ebrahimi Daryani N, Talebi M, Zali MR. Histological changes in refractory Helicobacter pylori infection and its relationship with increased levels of resistance to antibiotics and therapeutic regimens: one-year follow-up. APMIS 2020;128:25-34. [PMID: 31628820 DOI: 10.1111/apm.13001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Bruce M, Zulz T, Koch A. Surveillance of infectious diseases in the Arctic. Public Health 2016;137:5-12. [PMID: 27473191 DOI: 10.1016/j.puhe.2016.06.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
38 Dang NQH, Ha TMT, Nguyen ST, Le NDK, Nguyen TMT, Nguyen TH, Pham TTH, Tran VH. High rates of clarithromycin and levofloxacin resistance of Helicobacter pylori in patients with chronic gastritis in the south east area of Vietnam. J Glob Antimicrob Resist 2020;22:620-4. [PMID: 32590188 DOI: 10.1016/j.jgar.2020.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Lee SK, Lee SW, Park JY, Kwon BS, Kim SY, Hyun JJ, Kim JH, Jung SW, Koo JS, Yim HJ. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Helicobacter. 2011;16:410-414. [PMID: 21923688 DOI: 10.1111/j.1523-5378.2011.00870.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
40 Reva I, Takano T, Higuchi W, Iwao Y, Taneike I, Nakagawa S, Ike M, Pererva O, Tarankov A, Agapov M, Rizhkov E, Singur O, Reva G, Potapov V, Yamamoto T. Virulence genotypes and drug resistance of Helicobacter pylori from Vladivostok, Russia: another feature in the Far East: I. Reva et al. Microbiology and Immunology 2012;56:198-202. [DOI: 10.1111/j.1348-0421.2011.00425.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Bott AM, Bruce MG, Bulkow L, Coleman J, Hennessy TW. Trends in antimicrobial prescribing rates for Alaska Native and American Indian persons <18 years of age residing in the Anchorage region. Int J Circumpolar Health 2009;68:337-46. [PMID: 19917186 DOI: 10.3402/ijch.v68i4.17363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 McMahon BJ, Bruce MG, Koch A, Goodman KJ, Tsukanov V, Mulvad G, Borresen ML, Sacco F, Barrett D, Westby S, Parkinson AJ. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary. Epidemiol Infect 2016;144:225-33. [PMID: 26094936 DOI: 10.1017/S0950268815001181] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
43 Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39:1001-1005. [PMID: 17889627 DOI: 10.1016/j.dld.2007.06.016] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
44 Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 310] [Cited by in F6Publishing: 284] [Article Influence: 51.7] [Reference Citation Analysis]
45 Wu IT, Chuah SK, Lee CH, Liang CM, Lu LS, Kuo YH, Yen YH, Hu ML, Chou YP, Yang SC, Kuo CM, Kuo CH, Chien CC, Chiang YS, Chiou SS, Hu TH, Tai WC. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. World J Gastroenterol 2015; 21(37): 10669-10674 [PMID: 26457027 DOI: 10.3748/wjg.v21.i37.10669] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
46 Di Caro S, Franceschi F, Mariani A, Thompson F, Raimondo D, Masci E, Testoni A, La Rocca E, Gasbarrini A. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. Dig Liver Dis. 2009;41:480-485. [PMID: 18974025 DOI: 10.1016/j.dld.2008.09.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
47 Fuccio L, Zagari RM, Bazzoli F. What is the best salvage therapy for patients with Helicobacter pylori infection? Nat Clin Pract Gastroenterol Hepatol 2008;5:608-9. [PMID: 18797442 DOI: 10.1038/ncpgasthep1256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
48 Rispo A, Di Girolamo E, Cozzolino A, Bozzi R, Morante A, Pasquale L. Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter. 2007;12:364-365. [PMID: 17669111 DOI: 10.1111/j.1523-5378.2007.00517.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
49 Lee JY, Kim N, Nam RH, In Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter. 2019;24:e12660. [PMID: 31507036 DOI: 10.1111/hel.12660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
50 Cremades N, Velázquez-campoy A, Martínez-júlvez M, Neira JL, Pérez-dorado I, Hermoso J, Jiménez P, Lanas A, Hoffman PS, Sancho J. Discovery of Specific Flavodoxin Inhibitors as Potential Therapeutic Agents against Helicobacter pylori Infection. ACS Chem Biol 2009;4:928-38. [DOI: 10.1021/cb900166q] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
51 Gisbert JP, Fernández-Bermejo M, Molina-Infante J, Pérez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodríguez JM, Robledo-Andrés P, González-García G. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2007;26:495-500. [PMID: 17635384 DOI: 10.1111/j.1365-2036.2007.03384.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
52 Jodlowski TZ, Lam S, Ashby CR. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother. 2008;42:1621-1639. [PMID: 18845620 DOI: 10.1345/aph.1l234] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One. 2014;9:e85620. [PMID: 24465624 DOI: 10.1371/journal.pone.0085620] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
54 Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol. 2011;4:103-114. [PMID: 21694812 DOI: 10.1177/1756283x10384171] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
55 Williams K, Colquhoun A, Munday R, Goodman KJ; CANHelp Working Group. Antibiotic dispensation rates among participants in community-driven health research projects in Arctic Canada. BMC Public Health 2019;19:949. [PMID: 31307422 DOI: 10.1186/s12889-019-7193-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014; 20(29): 9898-9911 [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
57 Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter. 2009;14:77-85. [PMID: 19751431 DOI: 10.1111/j.1523-5378.2009.00709.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
58 Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol 2015; 21(21): 6698-6705 [PMID: 26074708 DOI: 10.3748/wjg.v21.i21.6698] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]